[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
The authors by placebo methods interrupted the antiparkinsonian treatment in chronic psychotic patients who had a neuroleptic treatment for at least three months. Three weeks after: 72 percent had to receive the antiparkinsonian they took before, in consequence of extrapyramidal manifestations (an half of the sample receive this antiparkinsonian during the first week), and more than a third presented an acute psychotic outbreak. However, 28 percent of the total sample were still with placebo. Authors are questioning the psychotropic activity of antiparkinsonians, the influence of neuroleptic doses and the specificity of each administred neuroleptic. They conclude in opposition with other authors, to the necessity of prescribing continuously antiparkinsonians in most of the cases of chronic psychoses, in long-term neuroleptic treatment.
D000328:Adult; D000978:Antiparkinson Agents / Q000008:administration & dosage*; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002746:Chlorpromazine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005476:Fluphenazine / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008134:Long-Term Care; D008297:Male; D010919:Placebos / Q000008:administration & dosage; D011618:Psychotic Disorders / Q000188:drug therapy*; D012008:Recurrence; D013375:Substance Withdrawal Syndrome; D013469:Sulpiride / Q000627:therapeutic use; D014149:Tranquilizing Agents / Q000627:therapeutic use*
D000978:Antiparkinson Agents; D010919:Placebos; D014149:Tranquilizing Agents; D013469:Sulpiride; D006220:Haloperidol; D005476:Fluphenazine; D002746:Chlorpromazine
Essai d'interruption des antiparkinsoniens dans les traitements neuroleptiques au long cours